The Pharma Letter M&A roundup - August 2023

4 September 2023

A sizeable sum in excess of $7.75 billion was spent across pharmaceutical M&A in August.

Among big pharma's big spenders were Novo Nordisk (NOVN: VX) and Gilead Sciences (Nasdaq: GILD), though the month's biggest deal was US health care tech conglomerate Danaher Corp's (NYSE: DHR) $5.7 billion buy of UK antibody research expert Abcam (AIM: ABC).

There were also some intriguing acquisitions during August. US drugmaker EQRx was founded on the principle of developing and delivering innovative medicines to patients at radically lower prices, but that ambition appears dead and buried now that the struggling firm is to be acquired by oncology drug developer Revolution Medicines (Nasdaq: RVMD). Japan's Otsuka Pharmaceuticals (TYO: 4578) also became the first sizeable pharma company to take a bite out of the emerging psychedelic medicines sector with its buy of Mindset Pharma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK